General contact information for trials in the Maritimes:
Nova Scotia:
- novascotia.canadiancancertrials.ca/
- Dr. Michael West, Assistant Dean of Research, Clinical Trials – Dalhousie University (902-473-4023, michael.west@cdha.nshealth.ca)
Nova Scotia:
Recruiting location in the Maritimes:
ID Number: NCT02935634
Links:
Description: This is a Phase III pilot trial. The participants in this study will be patients with Gastroesophageal Junction adenocarcinoma. The researchers want to know if perioperative chemotherapy or preoperative chemoradiotherapy is more helpful. This is a pilot study, which means that it is quite small and the researchers are trying to figure out if it is feasible to conduct a larger trial to answer their question with more data. They will compare the survival of two groups to try and find a better treatment for Gastroesophageal Junction cancer:
Intervention:
Can I consider participating?
Recruiting location in the Maritimes:
ID Number: NCT02773524
Links:
Description: This study is looking to determine if regorafenib improves survival in patients with advanced gastro-oesophageal carcinoma.
A: Regorafenib
B: Placebo
Intervention: Regorafenib is a targeted chemotherapy drug that is a tyrosine kinase inhibitor. It slows down or stops the growth of cancer cells.
Can I consider participating?
ACTIVE, no longer recruiting:
ID Number: NCT03221426
Links:
Description:This study is looking at the drug pembrolizumab (MK-3745) and its effectiveness before and after surgery treatment for gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Group A: Pembrolizumab and Chemotherapy
Group B: Placebo and Chemotherapy
Group C: Pembrolizumab and FLOT (docetaxel, oxaliplatin, 5-fluorouracil, leucovorin)
Group D: Placebo and FLOT
Intervention:Pembrolizuma is a drug which helps the immune system cells to attack and get rid of cancer cells. It is an immunotherapy medication. FLOT are combination chemotherapy drugs that attack the cancerous cells.
Can I consider participating?